{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:06:59Z","timestamp":1790611619874,"version":"4.1.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Some patients with chronic lymphocytic leukemia who develop progressive disease (PD) during covalent Bruton tyrosine kinase (BTK) inhibitor treatment acquire resistance mutations in BTK or PLCG2. Here, we report gene mutation data from paired baseline and PD peripheral blood samples from 52 patients (zanubrutinib, n\u00a0=\u00a024; ibrutinib, n\u00a0=\u00a028) who, at an early median follow-up of 25.7\u00a0months, progressed on zanubrutinib or ibrutinib treatment in ALPINE. No BTK mutations were observed at baseline; at PD, 8 patients (zanubrutinib, n\u00a0=\u00a05; ibrutinib, n\u00a0=\u00a03) acquired 17 BTK mutations, 82.4% (zanubrutinib, n\u00a0=\u00a011\/14; ibrutinib, n\u00a0=\u00a03\/3) at C481. Non-C481 mutations occurred in 12.5% (3\/24) of zanubrutinib-treated patients (L528W: n\u00a0=\u00a02; cancer cell fraction [CCF]\u00a0=\u00a09.58% and 17.6%; A428D: n\u00a0=\u00a01; CCF\u00a0=\u00a037.03%). At baseline, 48 of 52 patients had \u22651 driver gene mutation(s), most frequently in NOTCH1 (n\u00a0=\u00a021), TP53 (n\u00a0=\u00a019), BRAF (n\u00a0=\u00a010), SF3B1 (n\u00a0=\u00a08), and ATM (n\u00a0=\u00a08). At PD, acquired mutations occurred in 1 zanubrutinib-treated patient (TP53, XPO1) and 5 ibrutinib-treated patients (TP53, n\u00a0=\u00a01 patient; SETD2, n\u00a0=\u00a01; SF3B1, n\u00a0=\u00a01; ASXL1, n\u00a0=\u00a02). Baseline driver gene mutations were not associated with development of BTK mutations, but patients with \u22652 baseline driver gene mutations were more likely to acquire BTK mutations at PD. The short treatment duration and a low BTK mutations incidence suggests that mechanisms other than BTK\/PLCG2 mutations drive most early PD. This trial was registered at www.ClinicalTrials.gov as #NCT03734016.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014206","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T15:26:49Z","timestamp":1737732409000},"page":"1918-1926","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Acquired mutations in patients with relapsed\/refractory CLL who progressed in the ALPINE study"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Li","sequence":"additional","affiliation":[{"name":"2BeiGene Inc, San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara F.","family":"Eichhorst","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn K\u00f6ln D\u00fcsseldorf, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[{"name":"4Hematology\/Oncology Division, Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, University of California, Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"6Department of Haematology, Alfred Hospital and Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[{"name":"7National Clinical Research Center for Hematological Disorders, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"},{"name":"8Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Huang","sequence":"additional","affiliation":[{"name":"9BeiGene Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6713-9678","authenticated-orcid":false,"given":"Yang","family":"Shi","sequence":"additional","affiliation":[{"name":"10BeiGene Co, Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Idoine","sequence":"additional","affiliation":[{"name":"2BeiGene Inc, San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommi","family":"Salmi","sequence":"additional","affiliation":[{"name":"11BeiGene International GmbH, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen Cleary","family":"Cohen","sequence":"additional","affiliation":[{"name":"2BeiGene Inc, San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"12Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"5","key":"2025042208464394100_bib1","doi-asserted-by":"crossref","first-page":"e12931","DOI":"10.1111\/sji.12931","article-title":"B\u00a0cell signalling pathways\u2014new targets for precision medicine in chronic lymphocytic leukaemia","volume":"92","author":"Sk\u00e5nland","year":"2020","journal-title":"Scand J Immunol"},{"issue":"8","key":"2025042208464394100_bib2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2013-07-515361","article-title":"Bruton\u2019s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"issue":"25","key":"2025042208464394100_bib3","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"2025042208464394100_bib4","doi-asserted-by":"crossref","first-page":"630942","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"2025042208464394100_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-022-00756-9","article-title":"Chronic lymphocytic leukemia treatment algorithm 2022","volume":"12","author":"Hampel","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"2025042208464394100_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br J Haematol"},{"issue":"13","key":"2025042208464394100_bib7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025042208464394100_bib8","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/s41467-017-02329-y","article-title":"The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy","volume":"8","author":"Landau","year":"2017","journal-title":"Nat Commun"},{"issue":"7","key":"2025042208464394100_bib9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.2019000854","article-title":"Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study","volume":"134","author":"Quinquenel","year":"2019","journal-title":"Blood"},{"issue":"20","key":"2025042208464394100_bib10","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025042208464394100_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood-2023-180143","article-title":"Genomic evolution and resistance during pirtobrutinib therapy in covalent BTK-inhibitor (cBTKi) pre-treated chronic lymphocytic leukemia patients: updated analysis from the BRUIN study","volume":"142","author":"Brown","year":"2023","journal-title":"Blood"},{"issue":"S2","key":"2025042208464394100_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/hon.3164_163","article-title":"Characterization of mechanisms of resistance in previously treated chronic lymphocytic leukemia (CLL) from a head-to-head trial of acalabrutinib versus ibrutinib","volume":"41","author":"Woyach","year":"2023","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2025042208464394100_bib13","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2019-127674","article-title":"Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2025042208464394100_bib14","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2025042208464394100_bib15","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2023-178819","article-title":"Extended follow-up and resistance mutations in CLL patients treated with acalabrutinib","volume":"142","author":"Sun","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2025042208464394100_bib16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.2020008502","article-title":"How I treat chronic lymphocytic leukemia after venetoclax","volume":"138","author":"Lew","year":"2021","journal-title":"Blood"},{"issue":"10277","key":"2025042208464394100_bib17","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"2025042208464394100_bib18","author":"Eyre","year":"9-12  2022"},{"issue":"8","key":"2025042208464394100_bib19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2025042208464394100_bib20","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2025042208464394100_bib21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"12","key":"2025042208464394100_bib22","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","article-title":"BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib","volume":"7","author":"Bonfiglio","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2025042208464394100_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ijc.32502","article-title":"Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib","volume":"146","author":"G\u00e1ng\u00f3","year":"2020","journal-title":"Int J Cancer"},{"issue":"suppl 1","key":"2025042208464394100_bib24","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2019-125411","article-title":"BTK and\/or PLCG2 mutations in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: characteristics and outcomes at the time of progression","volume":"134","author":"Hampel","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2025042208464394100_bib25","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cncr.31831","article-title":"Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor\u2013resistant chronic lymphocytic leukemia with disease progression and Richter transformation","volume":"125","author":"Kanagal-Shamanna","year":"2019","journal-title":"Cancer"},{"key":"2025042208464394100_bib26","author":"Scarf\u00f2","year":"19-20  2020"},{"key":"2025042208464394100_bib27","author":"Santambrogio","year":"19-20  2020"},{"issue":"3","key":"2025042208464394100_bib28","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1158\/2159-8290.CD-19-1130","article-title":"Acalabrutinib plus obinutuzumab in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia","volume":"10","author":"Woyach","year":"2020","journal-title":"Cancer Discov"},{"issue":"suppl 1","key":"2025042208464394100_bib29","doi-asserted-by":"crossref","first-page":"9847","DOI":"10.1182\/blood-2022-159525","article-title":"Longitudinal mutation profiling in CLL patients during acalabrutinib therapy and at progression","volume":"140","author":"Sun","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2025042208464394100_bib30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2019-125488","article-title":"BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib","volume":"134","author":"Handunnetti","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2025042208464394100_bib31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.18162","article-title":"A\u00a0two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed\/refractory B-cell malignancies","volume":"198","author":"Song","year":"2022","journal-title":"Br J Haematol"},{"issue":"4","key":"2025042208464394100_bib32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"2025042208464394100_bib33","doi-asserted-by":"crossref","first-page":"591577","DOI":"10.3389\/fonc.2020.591577","article-title":"Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies","volume":"10","author":"Ondrisova","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"2025042208464394100_bib34","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41419-019-2158-0","article-title":"Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K\/AKT activation in B-cell lymphoid malignancies","volume":"10","author":"Kapoor","year":"2019","journal-title":"Cell Death Dis"},{"issue":"24","key":"2025042208464394100_bib35","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2025042208464394100_bib36","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2025042208464394100_bib37","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2643-3230.BCD-21-0063","article-title":"Overcoming acquired epigenetic resistance to BTK inhibitors","volume":"2","author":"Shaffer","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"11","key":"2025042208464394100_bib38","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","article-title":"Molecular map of chronic lymphocytic leukemia and its impact on outcome","volume":"54","author":"Knisbacher","year":"2022","journal-title":"Nat Genet"},{"key":"2025042208464394100_bib39","unstructured":"Predicine\n          . PredicineHEME CLIA validated NGS assay for hematologic malignancies. Accessed 10 February 2025. https:\/\/www.predicine.com\/wp-content\/uploads\/2023\/03\/PredicineHEME-Flyer-APM-00011-Rev-1-Gabriella-17March2023.pdf."},{"issue":"12","key":"2025042208464394100_bib40","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"suppl 1","key":"2025042208464394100_bib41","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1182\/blood-2023-173547","article-title":"Acquired mutations in patients (Pts) with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study","volume":"142","author":"Brown","year":"2023","journal-title":"Blood"},{"issue":"suppl","key":"2025042208464394100_bib42","doi-asserted-by":"crossref","first-page":"e8967737","DOI":"10.1097\/01.HS9.0000974472.89677.37","article-title":"BTK and PLCG2 gene mutations in chronic lymphocytic leukemia patients with resistance to covalent BTK inhibitor [abstract]","volume":"7","author":"Likold","year":"2023","journal-title":"Hemasphere"},{"issue":"6682","key":"2025042208464394100_bib43","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"issue":"14","key":"2025042208464394100_bib44","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2022009366","article-title":"BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib","volume":"7","author":"Jackson","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2025042208464394100_bib45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17474086.2018.1435268","article-title":"Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?","volume":"11","author":"Lampson","year":"2018","journal-title":"Expert Rev Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/1918\/2368429\/blooda_adv-2024-014206-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/1918\/2368429\/blooda_adv-2024-014206-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:46:55Z","timestamp":1745326015000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/8\/1918\/535268\/Acquired-mutations-in-patients-with-relapsed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,4,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014206","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}